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The aim of this study was to assess the in vivo effects of quercetin on pial microvas-
cular responses during transient bilateral common carotid artery occlusion (BCCAO) and
reperfusion. Rat pial microcirculation was visualized by ﬂuorescence microscopy through a
closed cranial window. Pial arterioles were classiﬁed in ﬁve orders of branchings. Capillar-
ies were assigned order 0, the smallest arterioles order 1, and the largest ones order 5. In
ischemic rats, 30min BCCAO and 60min reperfusion caused arteriolar diameter decrease
(by 14.5± 3.3% of baseline in order 2), microvascular leakage [0.47± 0.04, normalized
gray levels (NGL)], leukocyte adhesion in venules (9± 2/100μm venular length, v.l./30 s),
and reduction of capillary perfusion (by 40± 7% of baseline). Moreover, at the end of
BCCAO and reperfusion there was a signiﬁcant increase in reactive oxygen species (ROS)
formation when compared with baseline. Quercetin highest dose determined dilation in
all arteriolar orders (by 40± 4% of baseline in order 2) and prevented microvascular per-
meability (0.15± 0.02 NGL), leukocyte adhesion (3± 1/100μm v.l./30 s) as well as ROS
formation, while capillary perfusion was protected. Inhibition of endothelial nitric oxide
synthase (NOS) prior to quercetin reduced arteriolar dilation (order 2 diameter increase
by 10.3± 2.5% of baseline) and caused permeability increase (0.29± 0.03 NGL); inhibi-
tion of neuronal NOS or inducible NOS did not affect quercetin-induced effects. Inhibition
of guanylyl cyclase prior to quercetin reversed the quercetin’s effects on pial arteriolar
diameter and leakage. In conclusion, quercetin was able to protect pial microcirculation
from ischemia–reperfusion damage inducing arteriolar dilation likely by nitric oxide release.
Moreover, quercetin scavenger activity blunted ROS formation preserving the blood–brain
barrier integrity.
Keywords: bilateral common carotid artery occlusion, reperfusion, pial microcirculation, quercetin, endothelial
nitric oxide, vasodilation
INTRODUCTION
The cerebral transient hypoperfusion, induced in experimental
models by bilateral common carotid artery occlusion (BCCAO)
and followed by reperfusion, causes signiﬁcant microvascular
alterations. These are characterized by disruption of the blood–
brain barrier, edema, and swelling of perivascular astrocyte
foot processes, decrease in arteriolar endothelium-dependent
relaxation, altered expression of proteases, and matrix metal-
loproteinases, increase in inﬂammatory mediators (Chan, 1996;
Nakashima et al., 1999; Cho et al., 2006; Lapi et al., 2008a). Recent
data indicate that 30min of BCCAO and 45min of reperfusion
induce lipoperoxidation of brain tissue due to formation of reac-
tive oxygen species (ROS; Xu et al., 2002). On the other hand,
several studies, carried out in humans, have suggested a close rela-
tionship between cerebral ischemia and oxidative stress (Dugan
and Kim-Han, 2006). The cerebral tissue is vulnerable to the
effects of ROS, because under oxidative stress superoxide anion
and hydrogen peroxide cannot be readily neutralized due to the
low catalase, superoxide dismutase (SOD) and glutathione peroxi-
dase activities present in the brain. Furthermore, brain membrane
lipids are very rich in polyunsaturated fatty acids, which are sen-
sitive to free radical-induced peroxidation, likely one of the most
important events in cerebral cell damage (Del Zoppo, 1994; Pietta,
2000).
Drugs able to limit ischemia–reperfusion injury are free radi-
cal scavengers (antioxidant substances) and agents forming stable
adducts with free radicals, as previously shown. Therefore, antiox-
idant substances, particularly those ones present in food sources
such as ﬂavonoids, have been extensively studied (Ikeda et al.,
2003). Flavonoids have a wide range of activities in the prevention
of coronary heart disease, cancer, gastrointestinal disorders, and
inﬂammation (Moreira et al., 2004). They are polyphenolic com-
pounds, benzo-γ-pyrone derivatives, widely distributed in dietary
fruits and vegetables. One of the most available is quercetin which
represents about 60–75% of the average amount of ﬂavonoids in
the usual Western country diet (Rice-Evans, 2001).
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The in vivo protection exertedbyquercetin on cerebral ischemia
has been partially described in previous studies. Shutenko et al.
(1999) demonstrated that the intraperitoneal or intravenous
administration of quercetin in rats, subjected to ischemia and
reperfusion and sacriﬁed afterward, increases thenitric oxide (NO)
levels only in cerebral cortex with consequent reduction in super-
oxide levels and lowering of peroxynitrite formation. The results
of Kumura et al. (1996) support this hypothesis because they
found that the NO levels measured in jugular vein blood during
reperfusion after middle cerebral artery occlusion (2 h) are sig-
niﬁcantly increased by SOD treatment. Recent studies have shown
that quercetin induces vessel dilation by activation of theNOpath-
way in smooth muscle cells and triggers systemic and coronary
vasodilation (Ajay et al., 2003). Quercetin reduces blood pressure,
cardiac hypertrophy, and vascular remodeling in spontaneously
hypertensive and NO-deﬁcient rats (Lopez et al., 2004).
Recently, Ahmad et al. (2011) have shown quercetin dehy-
drate, intraperitoneally administered in rats, protects against neu-
ronal damage induced by transient middle cerebral artery occlu-
sion through prevention of free radical formation. However, the
mechanism of ﬂavonoid action still remains elusive.
Up to now, there are no data on the effects exerted by quercetin
on in vivo pial microvasculature and on its speciﬁc mechanism of
action.
The purpose of the present study was to investigate the in vivo
vascular effects of quercetin in preventing injury due to BCCAO
and reperfusion. Our suggestion was that quercetin could induce
vasodilation through the NO pathway; therefore, we studied the
effects of inhibiting endothelial nitric oxide synthase (eNOS) by
NG-nitro-l-arginine-methyl ester (L-NAME), or neuronal NOS
(nNOS)by 7-nitroindazole,or inducibleNOS (iNOS) by l-N 6-(1-
iminoethyl) lysine hydrochloride. Moreover, we used 1H-(1, 2, 4)
oxadiazolo (4,3-alpha) quinoxalin-1-one (ODQ) to inhibit guany-
lyl cyclase, known to be triggered by NO. The principal aim was to
analyze pial microvascular responses, such as arteriolar diameter
changes, permeability increase, leukocyte adhesion, and capillary
perfusion, after administration of quercetin in rats subjected to
BCCAO and reperfusion. In particular, we evaluated the pial arte-
riole changes by ﬂuorescence microscopy, because these vessels
constitute a complex surface network characterized by ﬁve orders
of vessels, supplying blood to superﬁcial layers of cerebral cortex
(Lapi et al., 2008b). We focused our attention on the responses
of order 2 arterioles, the most reactive to hypoperfusion due
to BCCAO. The neuronal physiological activity, indeed, depends
on adequate blood ﬂow supply; therefore, the pial microvascu-
lar behavior during BCCAO and reperfusion might be important
to evaluate changes in cerebral cortex blood ﬂow. Finally, we
evaluated ROS formation by 2′-7′-dichloroﬂuorescein-diacetate
(DCFH-DA) at the end of BCCAO and reperfusion.
MATERIALS AND METHODS
EXPERIMENTAL GROUPS
Male Wistar rats weighing 250–300 g (Harlan, Italy) were ran-
domly assigned to eight groups.
(1) The ﬁrst group was composed from animals not subjected
to BCCAO and reperfusion [Sham-Operated (S) group, n = 18].
Three animals were treated with artiﬁcial cerebrospinal ﬂuid
(aCSF) containing 250mM 2′-7′dichloroﬂuorescein-diacetate
(DCFH-DA), ﬁve animals were used for microvascular observa-
tions, ﬁve animals were utilized to evaluate the eNOS expression
by Western blotting and ﬁve animals were used to determine
neuronal damage by 2,3,5-Triphenyltetrazolium Chloride (TTC)
Staining. Moreover, sham-operated rats received intravenously
(i.v.) quercetin 1.0, 2.5, 5.0mg/kg body weight (b.w.; subgroup
SQ1, subgroup SQ2, and subgroup SQ3; n = 3, respectively) or i.v.
L-NAME (eNOS inhibitor) 10mg/kg b.w. (group SL, n = 3) or
i.v. 1H-(1, 2, 4) oxadiazolo (4, 3-alpha) quinoxalin-1-one (ODQ,
guanylyl cyclase inhibitor) 1.0mg/kg b.w. (group S,n = 3) or i.v. 7-
nitroindazole (nNOS inhibitor) 9.0mg/kg b.w. (group SN, n = 3)
or i.v. l-N 6-(1-iminoethyl) lysine hydrochloride (iNOS inhibitor)
5mg/kg b.w. (group SNI, n = 3). (2) Ischemic rats (group I,
n = 25) were treated with 1.5mL vehicle (physiological saline
solution), i.v. injected, and subjected to 30min of BCCAO and
60min of reperfusion. Three rats were treated with aCSF con-
taining 250mM DCFH-DA during BCCAO and three animals
during reperfusion (RE). Moreover, nine animals were utilized
for microvascular studies, ﬁve ones to evaluate the eNOS expres-
sion by Western blotting and ﬁve animals were used to determine
neuronal damage by TTC staining. (3) The third group (subgroup
Q1, n = 20; subgroup Q2, n = 2; and subgroup Q3, n = 25) was
treated with i.v. quercetin 1.0, 2.5, and 5.0mg/kg b.w., respectively.
In three rats, belonging to each subgroup Q1, Q2, and Q3, during
BCCAO and three rats during reperfusion were treated with aCSF
containing 250mM DCFH-DA. Nine animals belonging to each
subgroup Q1, Q2, and Q3 were utilized for microvascular studies,
while ﬁve animals belonging to each subgroup were used to eval-
uate the eNOS expression by Western blotting. In addition, ﬁve
animals belonging to subgroup Q3 were used to determine neu-
ronal damage by TTC staining. (4) The fourth group of animals
(groupLQ,n = 9) received i.v. L-NAME,10mg/kg b.w.,prior to i.v.
quercetin (5mg/kg b.w.) before BCCAO and at the beginning of
reperfusion. (5) The ﬁfth group of rats (group NQ,n = 9) received
i.v. 7-nitroindazole (9mg/kg b.w.) prior to i.v. quercetin (5mg/kg
b.w.) before BCCAO and at the beginning of reperfusion. (6) The
sixth groups of animals (group NIQ, n = 9) received i.v. l-N 6-(1-
iminoethyl) lysine chloride (5mg/kg b.w.) prior to i.v. quercetin
(5mg/kg b.w.) before BCCAO and at the beginning of reperfu-
sion. (7) The seventh group of rats (OQ group, n = 9) was treated
with i.v. injected 1H-(1, 2, 4) oxadiazolo (4, 3-alpha) quinoxalin-1-
one (ODQ; 1mg/kg b.w.) and i.v. quercetin (5mg/kg b.w.) before
BCCAO and at the beginning of reperfusion. (8) Finally, the last
groupof rats receivedL-NAME(10mg/kg b.w.; groupL,n = 9), i.v.
injected 10minbeforeBCCAOand at the beginning of reperfusion
(Tables 1 and 2).
ADMINISTRATION OF DRUGS
Quercetin solutions were obtained dissolving 1.0, 2.5, and
5.0mg/kg b.w. in 0.5mL of saline solution and i.v. infused
(3min) to the rats 10min before BCCAO and at the beginning
of reperfusion (Shutenko et al., 1999).
L-NAME (10mg/kg b.w.) (3), 7-nitroindazole (9mg/kg b.w.;
Bush and Pollak, 2000), l-N 6-(1-iminoethyl) lysine chloride
(5mg/kg b.w.; Sakamoto et al., 2005) were dissolved in 0.5ml of
saline solution, respectively;ODQ (1.0mg/kg b.w.; Zingarelli et al.,
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Table 1 | Drug treatment (T), doses and route of administration in the different experimental groups.
Group H/R N Group NO H/R N
T T
I Saline solution (1.5ml i.v.) 25 S Saline solution (1.5ml i.v.) 18
Q1 Quercetin (1mg/kg b.w. i.v.) 20 SQ1 Quercetin (1mg/kg b.w. i.v.) 3
Q2 Quercetin (2.5mg/kg b.w. i.v.) 20 SQ2 Quercetin (2.5mg/kg b.w. i.v.) 3
Q3 Quercetin (5mg/kg b.w. i.v.) 25 SQ3 Quercetin (5mg/kg b.w. i.v.) 3
LQ NG-nitro-L-arginine-methyl ester (10mg/kg b.w. i.v.)+Quercetin
(5mg/kg b.w. i.v.)
9 SL NG-nitro-L-arginine-methyl ester (10mg/kg b.w.
i.v.)+L-NAME
3
NQ 7-nitroindazole (9mg/kg b.w. i.v.)+Quercetin (5mg/kg b.w. i.v) 9 SO 1H-(1, 2, 4) oxadiazolo (4, 3-alpha) quinoxalin-1-one
(9mg/kg b.w. i.v.)+ODQ
3
NIQ L-N6-(iminoethyl) lysine hydrochloride (5mg/kg b.w.
i.v.)+Quercetin (5mg/kg b.w. i.v)
9 SN 7-nitroindazole (9mg/kg b.w. i.v.) 3
OQ 1H-(1, 2, 4) oxadiazolo (4, 3-alpha) quinoxalin-1-one (9mg/kg
b.w. i.v.)+Quercetin (5mg/kg b.w. i.v.)
9 SNI L-N6-(iminoethyl) lysine hydrochloride (5mg/kg b.w.
i.v.)
3
L NG-nitro-L-arginine-methyl ester (10mg/kg b.w. i.v.)+L-NAME 9
H/R: animals subjected to hypoperfusion and reperfusion and NO H/R animals not subjected to hypoperfusion and reperfusion, R: reperfusion, N: number of rats
utilized.
Table 2 | Drugs, doses and route of administration, type of treatment and time of administration in the different experimental groups.
Group Drug Administration (total volume) Treatment Time
S Saline solution 1.5ml i.v. No BCCAO/R Twice at 40min interval
SQ1 Saline solution+Quercetin 1.5ml i.v.+1mg/kg b.w. i.v No BCCAO/R Twice at 40min interval
SQ2 Saline solution+Quercetin 1.5ml i.v.+2.5mg/kg b.w. i.v No BCCAO/R Twice at 40min interval
SQ3 Saline solution+Quercetin 1.5ml i.v.+5mg/kg b.w. i.v No BCCAO/R Twice at 40min interval
SL Saline solution+L-NAME 1.5ml i.v.+10mg/kg b.w. i.v No BCCAO/R Twice at 40min interval
SO Saline solution+ODQ 1.5ml i.v.+9mg/kg b.w. i.v No BCCAO/R Twice at 40min interval
SN Saline solution+7-nitroindazole 1.5ml i.v.+9mg/kg b.w. i.v No BCCAO/R Twice at 40min interval
SNI Saline solution+
L-N6-(iminoethyl) lysine
hydrochloride
1.5ml i.v.+5mg/kg b.w. i.v No BCCAO/R Twice at 40min interval
Q1 Saline solution+Quercetin 1.5ml i.v.+1mg/kg b.w. i.v BCCAO/R 10min prior to BCCAO
and at R beginning
Q2 Saline solution+Quercetin 1.5ml i.v.+2.5mg/kg b.w. i.v BCCAO/R 10min prior to BCCAO
and at R beginning
Q3 Saline solution+Quercetin 1.5ml i.v.+5mg/kg b.w. i.v BCCAO/R 10min prior to BCCAO
and at R beginning
LQ Saline solution+L-NAME+
Quercetin
1.5ml i.v.+10mg/kg b.w. i.v+5mg/kg b.w. i.v. BCCAO/R 20 and 10min prior to
BCCAO and at R begin-
ning
NQ Saline solution+
7-nitroindazole+Quercetin
1.5ml i.v.+9mg/kg b.w. i.v+5mg/kg b.w. i.v. BCCAO/R 20 and 10min prior to
BCCAO and at R begin-
ning
NIQ Saline solution+
L-N6-(iminoethyl) lysine
hydrochloride+Quercetin
1.5ml i.v.+5mg/kg b.w. i.v+5mg/kg b.w. i.v. BCCAO/R 20 and 10min prior to
BCCAO and at R begin-
ning
OQ Saline solution+ODQ+
Quercetin
1.5ml i.v.+9mg/kg b.w. i.v+5mg/kg b.w. i.v. BCCAO/R 20 and 10min prior to
BCCAO and at R begin-
ning
L Saline solution+L-NAME 1.5ml i.v.+10mg/kg b.w. i.v BCCAO/R 10min prior to BCCAO
and at R beginning
BCCAO/R, bilateral common carotid occlusion and reperfusion.
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FIGURE 1 | Experimental design of drug administration and measurement
times. R: recording points. FITC: ﬂuorescent-dextran (70 kDa) and rhodamine
6G. So/I: solvent, 0.9% NaCl, and/or inhibitor administration (L-NAME, ODQ).
So/Q: solvent, 0.9% NaCl, and/or quercetin administration. BCCAO: bilateral
common carotid artery occlusion. Rhodamine 6G was injected after
FITC-dextran as a bolus and then infused during BCCAO and reperfusion.
1999) was suspended in ethanol and saline solution (1.2mg/mL).
Each substance was i.v. administered prior to quercetin (5.0mg/kg
b.w.) according to the protocol time schedule reported in Figure 1.
2′-7′-dichloroﬂuorescein-diacetate (DCFH-DA) was mixed
with aCSF to obtain a concentration of 250mM (Watanabe, 1998).
This solution was superfused over the pial surface for 15min dur-
ing ischemia or reperfusion. The drugs were purchased by Sigma
Chemical, St. Louis, MO, USA.
In pilot experiments quercetin was tested in different concen-
trations; we chose the highest dosage, 5mg/kg b.w., according to
our preliminary results and to previous data (Shutenko et al.,
1999). In preliminary experiments i.v. infusion of L-NAME at the
dosage of 10mg/kg b.w., chosen for the present study, abolished
vasodilation due to topical application of acetylcholine, 100μM
(n = 10), while the diameter increase was by 42.3± 3.2% of base-
line in sham-operated animals treated with acetylcholine, n = 10
(Moreau et al., 1995).
In pilot experiments nNOS and iNOS inhibitors were tested
in different concentrations; we chose the dose of 9 and 5mg/kg
for 7-nitroindazole and l-N 6-(1-iminoethyl) lysine hydrochlo-
ride, respectively, according to previous data (Zingarelli et al., 1999;
Sakamoto et al., 2005).
ANIMAL PREPARATION
Anesthesia was induced with α-chloralose (50mg/kg b.w., i.p.)
plus urethane (600mg/kg b.w., i.p.) and maintained with ure-
thane alone (100mg/kg b.w., i.v. every hour). Rats were tra-
cheotomized, paralyzed with tubocurarine chloride (1mg/kg·h,
i.v.) and mechanically ventilated with room air and supplemental
oxygen. The right and left common carotid arteries were isolated
for successive clamping. A catheter was placed in the left femoral
artery for arterial blood pressure recording and blood gases sam-
pling. Another catheter was placed in the right femoral vein for
injection of the ﬂuorescent tracers [ﬂuorescein isothiocyanate
bound to dextran, molecular weight 70 kDa (FD 70), 50mg/100 g
b.w., i.v. as 5% wt/vol solution in 3min administered just once
at the beginning of experiment after 30min of the preparation
stabilization; rhodamine 6G, 1mg/100 g b.w. in 0.3mL, as a bolus
with supplemental injection throughout BCCAO and reperfusion
(ﬁnal volume 0.3ml·100 g−1·h−1) to label leukocytes for adhesion
evaluation] and of drugs. Blood gas measurements were carried
out on arterial blood samples withdrawn from arterial catheter
at 30min time period intervals (ABL5; Radiometer, Copenhagen,
Denmark). Throughout all experiments,mean arterial blood pres-
sure (MABP), heart rate, respiratory CO2, and blood gases values
were recorded and maintained stable within physiological ranges.
Rectal temperature was monitored and preserved at 37.0 ± 0.5˚C
with a heating stereotaxic frame where the rats were secured.
To observe the pial microcirculation, a closed cranial win-
dow (4mm× 5mm) was implanted above the left frontoparietal
cortex (posterior 1.5mm to bregma; lateral, 3mm to the mid-
line; Ngai et al., 1988). To prevent overheating of the cerebral
cortex during drilling, cold saline solution was suffused on the
skull. The dura mater was gently removed and a 150-μm-thick
quartz microscope coverglass was sealed to the bone with den-
tal cement. The window inﬂow and outﬂow were assured by two
needles secured in the dental cement of the window so that the
brain parenchyma was continuously superfused with aCSF (Morii
et al., 1986; Hudetz et al., 1995). The rate of superfusion was
0.5mL/min controlled by a peristaltic pump. During superfusion
the intracranial pressure (ICP) was maintained at 5± 1mmHg
and measured by a Pressure Transducer connected to a computer.
The composition of the aCSF was: 119.0mM NaCl, 2.5mM KCl,
1.3mM MgSO4·7H2O, 1.0mM NaH2PO4, 26.2mM NaHCO3,
2.5mM CaCl2, and 11.0mM glucose (equilibrated with 10.0%
O2, 6.0% CO2, and 84.0% N2; pH 7.38± 0.02). The temperature
was maintained at 37.0± 0.5˚C.
The reduction of cerebral blood ﬂow was produced by place-
ment of two atraumatic microvascular clips for 30min on
common carotid arteries, previously isolated. After removing
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the clamp, the pial microcirculation was observed for 60min
(reperfusion period).
All experiments conform to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996) and to institu-
tional rules for the care and handling of experimental animals. The
protocol was approved by the “Federico II” University of Naples
Ethical Committee.
INTRAVITAL MICROSCOPY AND MICROVASCULAR PARAMETER
EVALUATION
Observations of pial vessels were conducted by a ﬂuorescence
microscope (Leitz Orthoplan) ﬁtted with long-distance objectives
[2.5×, numerical aperture (NA) 0.08; 10×,NA0.20; 20×,NA0.25;
32×, NA 0.40], a 10× eyepiece and a ﬁlter block (Ploemopak,
Leitz). Epiillumination was provided by a 100W mercury lamp
using the appropriate ﬁlters for FITC, for rhodamine 6G and a heat
ﬁlter (Leitz KG1). The pial microcirculation was televised with a
DAGE MTI 300RC low-light level digital camera and recorded
by a computer based frame grabber (Pinnacle DC 10 plus, Avid
Technology, MA, USA).
Microvascular measurements were made off-line using a
computer-assisted imaging software system (MIP Image, CNR,
Institute of Clinical Physiology, Pisa, Italy). The visualization
of pial microcirculation was carried out according to the pro-
tocol time schedule reported in Figure 1. Brieﬂy, recording of
microvascular images was performed for 1min every 5min dur-
ing substance administration, before BCCAO and at the beginning
of reperfusion. Afterward, recording was carried out every 10min
during BCCAO and the remaining reperfusion. The baseline con-
ditions were represented by microvascular values detected within
2min of FITC administration.
However, pial arteriole responses to the highest dose of
quercetin and to the different substances were homogeneous dur-
ing BCCAO and reperfusion. Therefore, we chose to present data
recorded under the baseline conditions, at the end of BCCAO and
at the end of reperfusion (RE).
Under baseline conditions, the arteriolar network was mapped
by stop-frame images and pial arterioles were classiﬁed accord-
ing to a centripetal ordering scheme (Strahler method, modiﬁed
according to diameter), as previously described (Lapi et al., 2008b).
In each animal one order 4 arteriole, two order 3, and two order 2
arterioles were studied during each experiment.
We tried to investigate the responses of each arteriolar order to
the experimental conditions. However, because the responses were
homogeneously distributed in the different arteriolar orders, we
chose to present only the data regarding order 2 vessels, the most
responsive arterioles. When there were differentiated arteriolar
responses, we pointed out these differences for each experimental
group. To clarify the time-dependent changes of arteriolar diam-
eter we chose to present the different patterns of order 2 arteriole
diameter responses only in Figure 2.
Arteriolar diameters were measured with a computer-assisted
method (MIP Image program, frame by frame). The results of
diameter measurements were in accord with those obtained by
shearing method (±0.5μm). To avoid bias due to single operator
measurements, two independent “blinded” operators measured
the vessel diameters. Their measurements overlapped in all cases.
FIGURE 2 |Time course plots of diameter changes in the experimental
groups. (A) Diameter changes of order 2 arterioles, expressed as percent
of baseline, under baseline conditions, during BCCAO and reperfusion in
S = sham-operated group, I = ischemic group, and in Q3 =quercetin
(5.0mg/kg b.w.) subgroup; (B) Diameter changes of order 2 arterioles,
expressed as percent of baseline, under baseline conditions, during
BCCAO and reperfusion in Q3 =quercetin (5.0mg/kg b.w.) subgroup,
LQ=L-NAME+quercetin (5.0mg/kg b.w.) group, OQ=1H-(1, 2, 4)
oxadiazolo (4, 3-alpha) quinoxalin-1-one (ODQ)+quercetin (5.0mg/kg b.w.)
group.˚p<0.01 vs. baseline; *p<0.01 vs. I group; #p<0.01 vs. Q3
subgroup.
The increase in permeability was calculated and reported as
normalized gray levels (NGL): NGL= (I–Ir)/Ir, where Ir is the
average baseline gray level at the end of vessel ﬁlling with ﬂuores-
cence (average of ﬁve windows located outside the blood vessels
with the same windows being used throughout the experimental
procedure), and I is the same parameter at the end of BCCAO
or RE. Gray levels ranging from 0 to 255 were determined by the
MIP Image program in ﬁve regions of interest (ROI) measuring
50μm× 50μm (10× objective). The same location of ROI dur-
ing recordings along the microvascular networks was provided by
a computer-assisted device for XY movement of the microscope
table.
Adherent leukocytes (i.e., cells on vessel walls that did not
move over a 30-s observation period) were quantiﬁed in terms
of number/100 μm of venular length (v.l.)/30 s using higher
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magniﬁcation (20× and 32×, microscope objectives). In each
experimental group 45 venules were studied.
Perfused capillary length (PCL) was measured by MIP image in
an area of 150μm× 150μm. In this system the length of perfused
capillaries is easily established by the automated process because
it is outlined by dextran (Colantuoni et al., 2005).
Mean arterial blood pressure (Viggo-Spectramed P10E2 trans-
ducer – Oxnard, CA, USA – connected to a catheter in the femoral
artery) and heart rate were monitored with a Gould Windo-
graf recorder (model 13-6615-10S, Gould, OH, USA). Data were
recorded and stored in a computer. Blood gas measurements
were carried out on arterial blood samples withdrawn from arter-
ial catheter at 30min time period intervals (ABL5; Radiometer,
Copenhagen, Denmark). The hematocrit was measured under
baseline conditions, at the end of BCCAO and at RE.
Furthermore, to determine the degree of perfusion decrease
during BCCAO, microvascular blood ﬂow by laser Doppler perfu-
sion monitoring (LDPM) was measured on the skull of all animals
by a Perimed PF5001 ﬂowmeter, using a probe (407; Perimed, Swe-
den) attached to the bone. The sampling rate was 32Hz and blood
ﬂow was expressed as perfusion units (PU).
Finally, single pial venule blood ﬂow, Q, was calculated accord-
ing to the following equation: Q = α × VCL × A, where α was
a constant, related to the vessel diameter, V CL was the red blood
cell centerline velocity and A was the cross-sectional area. How-
ever, we chose to present only LDPM and venular blood ﬂow
data of ischemic rats (I group) and quercetin-treated animals (Q3
subgroup) to simplify data presentation.
OXYGEN-REACTIVE SPECIES QUANTIFICATION
Artiﬁcial cerebrospinal ﬂuid containing 250mM DCFH-DA at
37.0± 0.5˚C was superfused over the pial surface. The lipophilic
DCFH-DA is a stable non-ﬂuorescent probe with a high cellular
permeability. DCFH-DA reacts with intracellular radicals to be
converted to its ﬂuorescent product (DCF). The remaining extra-
cellular DCFH-DA was washed out with aCSF. The intensity of
DCF ﬂuorescence is proportional to the intracellular ROS level.
The ﬂuorescence intensity was determined by the use of an
appropriate ﬁlter (522 nm) and the evaluation of NGL, with the
baseline represented by pial surface just superfused by DCFH-DA
(Watanabe, 1998).
WESTERN BLOT ANALYSIS
Protein concentrations were determined by the Bio-Rad protein
assay (Bio-Rad). Todetect the proteins of interest, speciﬁc antibod-
ies: anti-eNOS (mouse monoclonal antibody, 1:200, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-phosphorylated eNOS
[Rabbit (polyclonal) Anti-eNOS (pS116) phosphospeciﬁc anti-
body unconjugated, Invitrogen] and anti-β-actin (mouse mon-
oclonal, 1:1000, Sigma) were used. Immunoreaction was revealed
using anti-mouse IgG conjugated to peroxidase, 1:2000 (GE
Healthcare) by the ECL reagent (GE Healthcare). The optical
density of the bands was determined by Chemi Doc Imag-
ing System (Bio-Rad) and normalized to the optical density
of β-actin. eNOS and phosphorylated eNOS were evaluated
to deﬁne concentrations of the expressed and active proteins,
respectively.
2, 3, 5-TRIPHENYLTETRAZOLIUM CHLORIDE (TTC) STAINING
Rats were sacriﬁced after 30min BCCAO and 60min reperfusion.
Tissue damage was evaluated by 2,3,5-Triphenyltetrazolium Chlo-
ride (TTC) staining. The brains were cut into 1mm coronal slices
with a vibratome (Campden Instrument, 752 M). Sections were
incubated in 2% TTC for 20min at 37˚C and in 10% formalin
overnight. The necrotic area site and extent in each section were
evaluated by image analysis software (Image-Pro Plus; Bederson
et al., 1986).
STATISTICAL ANALYSIS
All reported values are means± SD. Data were tested for nor-
mal distribution with the Kolmogorov–Smirnov test. Parametric
(Student’s t tests, ANOVA, and Bonferroni post hoc test) or non-
parametric tests (Wilcoxon, Mann–Whitney, and Kruskal–Wallis
tests) were used; non-parametric tests were applied to compare
diameter and length data among experimental groups. Due to
the small sample size of DCFH-DA treated rats we used non-
parametric tests to compare the results obtained in these animals.
The statistical analysis was carried out by SPSS 14.0 statistical
package. Statistical signiﬁcance was set at p< 0.05.
RESULTS
Under baseline conditions pial arterioles were classiﬁed in ﬁve
orders according to diameter, length, and branching. Capillaries,
assigned order 0, originated from the smallest arterioles (order 1,
average diameter: 16.4 ± 2.1μmand average length: 155± 70μm;
n = 160). The largest pial arterioles, order 5, showed diameter of
62.8± 4.8μm and length of 1114± 350μm (n = 96). The values
of diameters and lengths were signiﬁcantly different among the
different arteriolar orders (p< 0.01; Lapi et al., 2008b).
SHAM-OPERATED ANIMALS
Sham-operated animals did not show changes in arteriolar diame-
ter nor increase in leakage nor adhesion of leukocytes nor decrease
in capillary perfusion during the same period of observation as in
the other experimental groups.
The rats treated with DCFH-DA superfusion (n = 3) showed
no signiﬁcant increase in DCF ﬂuorescence intensity at the end of
observations (0.03± 0.01 NGL), indicating no ROS formation.
The sham-operated animals treatedwith quercetin (at the doses
of 1.0 or 2.5 or 5.0mg/kgb.w.) showed adose-dependent dilatation
of all arterioles (order 2 arterioles: by 12 ± 3% of baseline, at the
highest dosage, p< 0.01 vs. baseline), but no signiﬁcant changes
in the other parameters when compared with baseline (Table 3).
L-NAME, ODQ, 7-nitroindazole, and l-N 6-(1-iminoethyl) lysine
chloride did not signiﬁcantly affect diameter of vessels nor the
other parameters.
BCCAO-REPERFUSION
At the end of BCCAO ischemic animals (group I ) showed a
decrease in diameter of all arteriolar orders; in order 2 ves-
sels the reduction was by 19.0± 3.2% of baseline (Figure 2A),
while MABP did not signiﬁcantly change compared with baseline
(Table 4). Venular permeability signiﬁcantly increased compared
with baseline (p< 0.01); no changes in venular diameter were
detected, while most capillaries were not perfused.
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Table 3 |Variations of the main parameters in sham-operated (S) group, ischemic (I ) group, and quercetin (Q3) subgroup (5mg/Kg b.w.),
NG-nitro-L-arginine-methyl ester plus quercetin (LQ) group, 7-nitroindazole plus quercetin (NQ) group, L-N6-(l-iminoethyl) lysine hydrochloride
plus quercetinA (NIQ), and 1H-(1, 2, 4) oxadiazolo (4, 3-alpha) quinoxalin-1-one plus quercetin (OQ) group at the end of reperfusion.
Group Arteriolar
diameter (%)
Microvascular
permeability (NGL)
Leukocyte adhesion (Number
of leukocyte/100μm
of venular length/30s)
Capillary
perfusion (%)
S 100.0±5.0 0.02±0.01 1.0±0.5 100±4
I 85.5±3.3˚ 0.47±0.04˚ 9.0±2.0˚ 60±7˚
Q3 140.0±4.0˚* 0.15±0.02˚* 3.0±1.0˚* 90±4˚*
LQ 110.3±2.5*# 0.29±0.03˚*# 4.0±1.0˚* 83±4*
NQ 142.0±6.0˚* 0.17±0.03˚* 3.0±1.0˚* 88±6˚*
NIQ 144.0±5.0˚* 0.14±0.04˚* 4.0±1.0˚* 87±5˚*
OQ 93.7±3.0# 0.35±0.03˚*# 3.0±2.0* 72±4˚*
L 86.0±2.5˚ 0.48±0.05˚ 8.5±1.5˚ 61±3˚
Arteriolar diameter and capillary perfusion are reported as percent changes of 100% baseline values. NGL, normalized gray levels. ˚p<0.01 vs. S group; *p<0.01 vs.
I group; #p<0.01 vs. Q3 subgroup.
Table 4 | Mean arterial blood pressure (MABP) under baseline
conditions, at the end of bilateral common carotid artery occlusion
(BCCAO) and at the end of reperfusion (RE) in sham-operated (S)
group, ischemic (I ) group, and quercetin (Q3) subgroup (5mg/kg
b.w.), NG-nitro-L-arginine-methyl ester plus quercetin (LQ) group,
7-nitroindazole plus quercetin (NQ) group, L-N6-(l-iminoethyl) lysine
hydrochloride plus quercetina (NIQ), and 1H-(1, 2, 4) oxadiazolo (4,
3-alpha) quinoxalin-1-one plus quercetin (OQ) group.
Group Baseline (mmHg) BCCAO (mmHg) RE (mmHg)
I 101.0±3.5 99.0±4.0 100.0±3.5
Q3 104.0±5.5 102.0±4.0 103.0±5.0
LQ 105.0±5.0 103.0±5.5 104.0±4.0
NQ 102.0±4.0 99.0±5.0 101.0±4.5
NIQ 103.0±5.0 100.0±4.5 102.0±3.0
OQ 100.0±4.5 98.0±4.0 100.0±3.5
Values are means±SD.
At reperfusion, all arteriolar orders presented a triphasic
response, because at ﬁrst order 2 arterioles constricted by
13.5± 3.2% of baseline; then dilated by 10.0± 2.2% of baseline; at
RE they constricted again by 14.5± 3.3% of baseline (Figure 2A).
MABPdidnot change at allmeasurement points (Table 4).Venular
diameter did not vary; venular permeability signiﬁcantly increased
(Figures 3A,B; p< 0.01 compared with baseline) and leukocyte
adhesionwasmarked (9.0± 2.0/100μmv.l./30 s;p< 0.01 vs. base-
line) in venules (diameter 20–50 μm, n = 45), while capillary
perfusion length (PCL) decreased (p< 0.01 vs. baseline; Table 3).
At the end of BCCAO, microvascular blood ﬂow recorded
by LDPM on the contralateral parietal skull was reduced by
60.5± 4.5% of baseline (p< 0.01 vs. baseline, 36.2± 3.5 PU).
In single pial venules (SPV, diameter 30–40μm) the blood ﬂow
was reduced by 63.5± 6% of baseline (p< 0.01 vs. baseline:
247± 10 nL/s). At the beginning of reperfusion there was an
increase in blood ﬂow (reactive hyperemia), but within 6± 2min
the microvascular blood ﬂow, recorded by LDPM, decreased by
FIGURE 3 | Computer-assisted image of a pial microvascular network
under baseline conditions (A) and at the end of reperfusion (B) in an
ischemic rat.The increase in permeability is outlined by the marked change
in the color of interstitium (from black to white). Computer-assisted image
of a pial microvascular network under baseline conditions (C) and at the end
of reperfusion (D) in a quercetin-treated rat (5.0mg/kg b.w.), where there
was no leakage of ﬂuorescent-dextran. Scale bar=100μm.
35.0± 3.5% of baseline up to the end of observations. At RE,
SPV blood ﬂow was reduced by 30± 7% of baseline (p< 0.01 vs.
baseline).
The rats treated with DCFH-DA superfusion (n = 3) showed
an increased DCF ﬂuorescence intensity at the end of BCCAO
(0.20± 0.03 NGL, p< 0.01 vs. S group), indicating an increase in
ROS formation. The ﬂuorescence was higher at RE in the remain-
ing animals (n = 3; 0.32± 0.04NGL,p< 0.01 vs. S group) showing
a further increase in ROS production.
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QUERCETIN
Quercetin, administered at the doses of 1.0 or 2.5 or 5.0mg/kg b.w.
(subgroup Q1, Q2, and Q3, respectively), caused dose-dependent
effects. At the highest dose, there was an increase in all arterio-
lar diameters at the end of BCCAO: by 13.4± 3.4% of baseline in
order 2 (p< 0.01 vs. I group;Figure 2A). No signiﬁcant changes in
MABP were detected (Table 4). Leakage was signiﬁcantly reduced
compared with ischemic rats (p< 0.01).
At RE all pial arterioles dilated: by 40± 4% of baseline in order
2 (p< 0.01 vs. I group; Figure 2A). MABP did not signiﬁcantly
change at this time of observation (Table 4). Leakage of FD70 was
prevented as well as leukocyte adhesion (Figures 3C,D; p< 0.01
vs. I group), while capillary perfusion was protected (p< 0.01 vs.
I group; Table 3).
Quercetin highest dosage increased microvascular blood ﬂow
by 8± 2% of baseline (p< 0.01 vs. baseline) as detected by LDPM
on the contralateral parietal skull prior to BCCAO. At the end
of BCCAO, LDPM measurements indicated that quercetin pre-
vented the marked reduction in microvascular blood ﬂow as
observed in ischemic rats. The decrease was by 25± 5% of base-
line (p< 0.01 vs. baseline and I group). Similar results were
found for SPV blood ﬂow, reduced by 33.5± 5.0% of baseline:
235± 12 nl/s, p< 0.01 vs. baseline and I group, at the end of
BCCAO.
At the beginning of reperfusion there was steep increase in
blood ﬂow (reactive hyperemia); at the end of reperfusion blood
ﬂow increased by 39± 4% of baseline (p< 0.01 vs. baseline and
I group). At RE, SPV blood ﬂow was signiﬁcantly increased
by 50± 6% of baseline (p< 0.01 vs. baseline); the difference
was statistically signiﬁcant when compared with ischemic rat
response.
In the animals treated with DCFH-DA, the effects of quercetin
were dose-dependent. At the highest dosage, quercetin decreased
ROS formation at the end of BCCAOand at RE:NGL, indeed,were
0.08± 0.03 (p< 0.01 vs. I group, n = 3) and 0.16± 0.03 (p< 0.01
vs. I group, n = 3), respectively.
NO SYNTHASE INHIBITION PLUS QUERCETIN
At the end of BCCAO, L-NAME prior to quercetin (group LQ)
caused reduction in diameter of all arteriolar orders: by 4.5± 1.0%
of baseline in order 2 (p< 0.05 vs. I and p< 0.01 vs. Q3 groups;
Figure 2B), while MABP did not signiﬁcantly change (Table 4).
Leakage was reduced compared with ischemic animals (p< 0.01
vs. I group).
AtRE,all arterioles dilated: by 10.3 ± 2.5%of baseline in order 2
(p< 0.01 vs. I group; Figure 2B). MABP did not signiﬁcantly vary
(Table 4). The protective effect of quercetin on leakage was atten-
uated (p< 0.01, vs. I and Q3 groups). The adherent leukocytes
were reduced and PCL decreased (p< 0.01 vs. I group; Table 3).
L-NAME administered 10min before quercetin, prior to BCCAO,
did not signiﬁcantly affect arteriolar diameter and microvascular
permeability.
NEURONAL NO SYNTHASE INHIBITION PLUS QUERCETIN
The inhibition of nNOS by 7-nitroindazole prior to quercetin
(group NQ) did not affect quercetin-induced responses
(Table 3).
INDUCIBLE NO SYNTHASE INHIBITION PLUS QUERCETIN
The selective inhibition of iNOS by l-N 6-(1-iminoethyl) lysine
hydrochloride prior to quercetin (group NIQ) did not inﬂuence
quercetin-induced effects (Table 3).
GUANYLYL CYCLASE INHIBITION PLUS QUERCETIN
At the end of BCCAO, ODQ prior to quercetin (group OQ)
induced a decrease in diameter of all arterioles: by 9.0± 3.2%
of baseline in order 2 (p< 0.01 vs. Q3 subgroup; Figure 2B), but
MABP did not signiﬁcantly change (Table 4). Leakage increased
as in ischemic animals (p =NS vs. I group).
At RE all arterioles constricted: by 6.3± 3.0% of baseline in
order 2 (p< 0.01 vs. Q3 subgroup; Figure 2B), without signiﬁ-
cant changes in MABP (Table 4). Leakage was slightly attenuated
(p< 0.01 vs. I and Q3 groups), while the adherent leukocytes
were reduced in number (p< 0.01 vs. I group) and capillary per-
fusion was higher than in ischemic animals (p< 0.01 vs. I and
Q3 groups; Table 3). ODQ administered 10min before quercetin
prior to BCCAO did not signiﬁcantly affect arteriolar diameter
and microvascular permeability.
L-NAME PRIOR TO BCCAO AND REPERFUSION
The inhibition of NOS by L-NAME (L group) did not signiﬁcantly
inﬂuence the microvascular changes observed in rats submitted to
BCCAO and reperfusion (Table 3).
Finally, physiological parameters, such as hematocrit, MABP,
heart rate, pH, PCO2, and PO2 did not change in the different
experimental groups up to RE.
eNOS EXPRESSION
Western blot analysis showed that at the end of reperfusion eNOS
protein concentration signiﬁcantly increased in animals treated
with quercetin compared with I and S group. The eNOS protein
concentrations was the higher in hippocampus and cortex, while
the lower was detected in striatum of all animals. Both total and
phosphorylated eNOS proteins increased to the same extent. In S
group the striatum eNOS protein concentration was the highest
compared with the other groups (Figure 4).
TISSUE DAMAGE EVALUATION
The neuroprotective effects of quercetin administration were
assessed by evaluating damaged area after 30min BCCAO and
60min reperfusion. Ischemic rats showed a clear lesion, index
of striatum neuronal loss in both hemispheres, while cortex
did not show any signiﬁcant macroscopic damage. Highest dose
quercetin signiﬁcantly reduced neuronal injury compared with
that observed in ischemic animals (Figure 5).
DISCUSSION
The data reported in the present study indicate that the bilateral
occlusion of common carotid artery induced marked modiﬁca-
tions of pial microvasculature affecting the microenvironment
vital for the central nervous system functions.
In ischemic rats pial arteriolar diameter decreased during
hypoperfusion while during reperfusion the arterioles showed an
interesting triphasic response. It is reasonable to suggest that the
changes in vascular tone were due to smooth muscle cell activ-
ity, contracting at the beginning of reperfusion in response to
Frontiers in Physiology | Vascular Physiology March 2012 | Volume 3 | Article 32 | 8
Lapi et al. Quercetin and cerebral ischemia–reperfusion
FIGURE 4 |Western blotting of eNOS expression (A) and phosphorylated
eNOS expression (B) in three cerebral zones (cortex, striatum,
hippocampus) at the end of reperfusion in sham- operated group, in Q3,
quercetin-treated (5.0mg/kg b.w.) subgroup and in I group, and the
corresponding densitometric values (mean±SD). *p<0.01 vs. S
group,˚p<0.01 vs. I group.
the increase in blood pressure. Then, they relaxed for several
minutes and constricted again at the end of reperfusion. These
responses might be related to myogenic mechanisms; however, in
additional experiments we observed myosin light chain expres-
sion did not increase, while was enhanced myosin light chain
phosphorylation (data not reported). LDPM recordings, indeed,
indicated an increase in microvascular blood ﬂow at the beginning
of reperfusion, followed by a decrease after fewminutes. Therefore,
reperfusion caused reactive hyperemia, as observed in different
experimental models, and consequent changes in vessel diameter
(Hori and Kitakade, 1991; Tsapenko et al., 2001). However, there
were no signiﬁcant variations in the MABP recorded through the
femoral artery.
Microvascular permeability was pronounced indicating a
severe impairment of the blood–brain barrier; the venular ves-
sels showed many adherent leukocytes and almost half of the
capillaries were not perfused. In our preparation we found an
increase in leukocyte adhesion as observed primarily in the model
of transient middle cerebral artery occlusion in animals implanted
with a closed cranial window (Del Zoppo, 1994). Discrepancies in
leukocyte sticking, reported in different experimental conditions,
could be related to the different time period of ischemia, as dis-
cussed by Abels et al. (2000). Our data indicate that leukocyte
adhesion may be facilitated by at least 30min of hypoperfusion.
Bilateral common carotid artery occlusion model was intro-
duced by Eklöf and Siesjö (1972, 1973) to investigate cerebral
circulation damage and neuronal function impairment. Iwasaki
et al. (1989) demonstrated that 30min of BCCAO are sufﬁcient to
cause neuronal injury in the hippocampus and cerebral cortex.
Quercetin was dose-dependently able to ameliorate pial
microvascular alterations caused by BCCAO and reperfusion.
During hypoperfusion the pial arterioles showed a slight increase
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FIGURE 5 |TTC staining of coronal brain slice from a rat submitted to
BCCAO and reperfusion.The lesion in the striatum is outlined by the
dashed black line (A). TTC staining of coronal brain slice from a rat treated
with highest dose quercetin (5.0mg/kg b.w.; subgroup Q3) and submitted
to BCCAO and reperfusion, where there was reduced injury (B).
in diameter, but a signiﬁcant dilation at the end of reperfusion;
microvascular permeability was prevented as well as adhesion of
leukocytes to venular walls. Most capillaries were perfused when
compared with ischemic animals. These ﬁndings corresponded
to LDPM measurements and single venule blood ﬂow estima-
tion: under baseline conditions, quercetin was able to increase
blood ﬂow; at the end of BCCAO microvascular blood ﬂow was
signiﬁcantly higher than in ischemic animals; ﬁnally, at the end
of reperfusion the increase in perfusion was highly signiﬁcant.
These hemodynamic changes were accompanied by the increase
in eNOS expression, both total and phosphorylated eNOS pro-
teins, in hippocampus, and cerebral cortex induced by quercetin,
as detected by Western blotting. Finally, we observed highest dose
quercetin reduced striatum neuronal damage induced by BCCAO
and reperfusion, as detected by TTC staining.
The arteriolar dilation triggered by quercetin, higher at the end
of reperfusion than in sham-operated animals, may be strength-
ened by reactive hyperemia after transient ischemia, as observed
in experimental models or in human forearm after high pressure
cuff inﬂation. In this case, it is possible to observe a peak increase
in blood ﬂow after brachial artery occlusion for few minutes. The
higher reactivity caused by quercetin may be due to NO release by
arteriolar walls, facilitated in this response by changes in vascular
hemodynamics during recovery of reperfusion after brain hypop-
erfusion. These effects might have been produced by shear stress
and consequent NO release, because of larger NOS expression,
quickly triggered within 30min of hypoperfusion and 60min of
reperfusion.
Quercetin, a key representative ﬂavonoid molecule of the
polyphenol compounds present in fruits and vegetables, has been
widely studied, showing beneﬁcial and deleterious effects on dif-
ferent cell types (Dajas et al., 2003). This ﬂavonoid presents dose-
related biphasic effects, because low concentrations of quercetin
are able to activate some intracellular signaling pathways, inhib-
ited at high doses (Chen and Pace-Asciak, 1996). In particular,
protein kinase C and tyrosine kinase signaling pathways have been
reported to be modulated by quercetin in different experimental
models (Picq et al., 1989;Cogolludo et al., 2007;Negash et al., 2007;
Chiwororo and Ojewole, 2010). However, after so many studies
quercetin’s mechanism of action remains unclear.
Previous study has demonstrated that during ischemia–
reperfusion injury in rabbit hind limb (2.5 h ischemia, 2 h reperfu-
sion), quercetin protects skeletal muscle by scavenging superoxide,
and enhancing cytoprotective nitric oxide concentration. More-
over,Shutenko et al. (1999) conﬁrmed that the intravenous admin-
istration of quercetin in rats subjected to ischemia and reperfusion
increased the NO levels in the cerebral cortex. On the other hand,
inhibition of eNOSby L-NAMEdid not inﬂuence dilation induced
by quercetin in isolated rat thoracic aorta.
To clarify the intracellular pathways involved in the quercetin-
induced vasodilation, we tested, as ﬁrst approach, the effects of
L-NAME, eNOS inhibitor, prior to quercetin. We observed that
the inhibition of eNOS caused a signiﬁcant attenuation of arte-
rial dilation induced by quercetin, with arterioles dilating by
10.3± 2.5% of baseline. The quercetin’s protective effect on venu-
lar permeability was reduced while leukocyte adhesion decreased.
Consequently,quercetin effects appear to be complex, likely related
to more than one intracellular signaling pathway. L-NAME dosage
we used did not cause a signiﬁcant increase in arterial blood pres-
sure in our experiments as previously detected (Moreau et al.,
1995).
The guanylyl cyclase inhibition by ODQ before quercetin,
administered prior to BCCAO and at reperfusion beginning,
caused moderate constriction of all pial arteriolar orders, indi-
cating that the main effect of quercetin on arteriolar diameter was
mediated by NO release. The consequent activation of guanylyl
cyclase triggered the vessel smooth muscle cell relaxation. More-
over, ODQ caused increase in permeability of blood–brain barrier
and decrease in capillary perfusion. However, ODQ did not affect
leukocyte adhesion, prevented to the same extent as by quercetin
alone. Interestingly nNOS and iNOS inhibition did not affect
protection exerted by quercetin.
It is important to note NO exerts several functions activating
or inhibiting different intracellular pathways. NO derived from
endothelial cells causes vasodilation, decrease in vascular resis-
tance and blood pressure, inhibition of platelet aggregation and
adhesion, inhibition of leukocyte adhesion and migration. These
NO functions are mediated by cyclic GMP synthesized through
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soluble guanylyl cyclase, a heme-containing enzyme, which is
directly activated by NO (Toda et al., 2009).
Previous experiments carried out by in vitro methods indicated
the scavenger activity of quercetin (Lopez et al., 2004; Moreira
et al., 2004; Cho et al., 2006). Recently, Ahmad et al. (2011)
showed quercetin administration in rats submitted to transient
middle cerebral artery occlusion upregulates the antioxidant sta-
tus and lowers thiobarbituric acid reactive substance (TBARS)
levels, reducing the infarct size and neurological deﬁcits. We tried
to assess the in vivo effects of quercetin on ROS formation utilizing
the ﬂuorescent DCF, able to reveal ROS generation in tissues. Our
data show that quercetin was dose-dependently able to decrease
ﬂuorescent spots located outside the vessels; the decrease was
signiﬁcant when compared with DCF ﬂuorescence observed in
ischemic rats. Therefore, quercetin may signiﬁcantly reduce ROS
formation through a direct scavenger activity. The present paper
conﬁrm that 30min of BCCAO and 60min of reperfusion cause
ROS formation, able to cause lipoperoxidation, as reported by
Yampallewar et al. (2004). However, the small sample size of our
study requires further experiments to increase the number of
observations.
All these data indicate that NO release triggered by quercetin
may play a key role for dilation of arterioles and preservation of
blood–brain barrier, facilitating capillary perfusion, while leuko-
cyte adhesion appears to be mainly related to ROS formation. The
increase in ROS may facilitate adhesion of leukocytes to venular
walls, contributing to blood–brain barrier disruption and increase
in tissue damage due to increase in perivascular edema.
Therefore, our results are in agreement with previous ﬁndings
(Shutenko et al., 1999; Ahmad et al., 2011) supporting quercetin-
inducedprotective effects byNOreleasemodulation and scavenger
activity. However, it is worth noting for the ﬁrst time in the
present study quercetin was shown to prevent leukocyte adhe-
sion and capillary perfusion decrease induced by hypoperfusion
and reperfusion in pial networks.
In conclusion, in the present experimental preparation
quercetin was able to prevent permeability increase and leuko-
cyte sticking. These effects accompanied an increase in arteriolar
diameter and protection of capillary perfusion. Our data indi-
cate that quercetin’s effect may be observed in the in vivo rat
model of brain hypoperfusion and reperfusion. These quercetin’s
properties appear to be related mostly to an increase in eNOS
expression, NO release, and activity. The resulting arteriolar dila-
tion can contribute to the increase in arteriolar shear stress,
known to enhance further release of NO with the decrease in
platelet and leukocyte adhesion and increase in capillary viabil-
ity. Finally, quercetin scavenger activity, which reduces formation
of ROS known to be deleterious to vessel walls and to blood–
brain barrier, contributes to the overall protection exerted by
quercetin.
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